Home > Newsletters > International Pharmaceutical Regulatory Monitor > U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
International Pharmaceutical Regulatory Monitor
September 2012 | Vol. 40 No. 9
U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
The U.S. Food and Drug Administration (FDA) continues to approve cancer drugs more quickly than the European Medicines Agency (EMA), clearing them in about half the time regardless of the drug’s designation, according to a recent study.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.